DiscoverThe Genetics PodcastEP 212: A hub-and-spoke model for accelerating rare disease drug development with Ananth Sridhar and Sun-Gou Ji of BridgeBio
EP 212: A hub-and-spoke model for accelerating rare disease drug development with Ananth Sridhar and Sun-Gou Ji of BridgeBio

EP 212: A hub-and-spoke model for accelerating rare disease drug development with Ananth Sridhar and Sun-Gou Ji of BridgeBio

Update: 2025-11-06
Share

Description

Summary: 

This week on The Genetics Podcast, Patrick is joined by BridgeBio’s Ananth Sridhar, Chief Operating Officer of Cardiorenal Programs, and Sun-Gou Ji, Vice President of Computational Genomics. They discuss the hub-and-spoke model for de-risking and accelerating rare disease drug development, the role of human genetics in target discovery, lessons from their autosomal dominant hypocalcemia type 1 (ADH1) program, and how portfolio design and predictive genomics are shaping the future of precision medicine.


Show Notes: 

0:00 Intro to The Genetics Podcast

00:59 Welcome to Ananth & Sun-Gou

01:57 How BridgeBio’s hub-and-spoke model de-risks and accelerates rare disease drug development

06:45 How programs move from the hub to the spokes in target discovery and development

09:10 Translating a target into a therapy for autosomal dominant hypocalcemia type 1 (ADH1)

12:28 Challenges in ADH1 drug development and using population genetics to identify patients with gain-of-function variants

18:08 Under-diagnosis and incomplete penetrance in rare disease and quantifying genetic versus phenotypic prevalence

20:52 Balancing first-in-class innovation with risk management in rare disease drug development

24:24 Evaluating rare disease programs using risk-adjusted net present value (NPV) instead of peak sales

27:20 Key factors that can make rare disease programs faster and cheaper to develop, and why modality agnosticism is important

32:00 Sun-Gou’s experience in computational genetics and building data-driven infrastructure for discovery

36:44 Ananth’s lessons from Regeneron and applying patient-centered principles to rare disease drug development

39:00 Sun-Gou on the power of newborn sequencing and personal lessons from early diagnosis

43:36 Ananth’s views on making predictive medicine more personal and human-centered

44:51 Closing remarks

Find out more

Please consider rating and reviewing us on your chosen podcast listening platform! 

https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link


Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

EP 212: A hub-and-spoke model for accelerating rare disease drug development with Ananth Sridhar and Sun-Gou Ji of BridgeBio

EP 212: A hub-and-spoke model for accelerating rare disease drug development with Ananth Sridhar and Sun-Gou Ji of BridgeBio

Sano Genetics